Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment

Palbociclib, ribociclib and abemaciclib were recently approved as chemotherapeutic agents and are currently in the post-marketing surveillance phase. They are used in combination with aromatase inhibitors anastrozole and letrozole or antiestrogen fulvestrant for HR+, HER2− breast cancer treatment. H...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Lu Turković, Luka Bočkor, Oscar Ekpenyong, Tajana Silovski, Mila Lovrić, Slaven Crnković, Biljana Nigović, Miranda Sertić
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Subjects:	CDK4/6 inhibitors breast cancer palbociclib ribociclib abemaciclib anastrozole
Online Access:	https://www.mdpi.com/1424-8247/15/5/614

Similar Items

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
by: Daniela Maria Calucică, et al.
Published: (2022-12-01)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Evaluation of Electrocardiographic Repolarization Parameters in Patients who Received Ribociclib and Palbociclib Therapy
by: Gülçin Sahingöz Erdal, et al.
Published: (2023-07-01)

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer
by: Mahtani RL, et al.
Published: (2019-01-01)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
by: Benlong Yang, et al.
Published: (2025-05-01)

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
by: Shereen Elazzazy, et al.
Published: (2024-07-01)

Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
by: Tugay Avci, et al.
Published: (2025-03-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis
by: Yiyuan Liu, et al.
Published: (2023-08-01)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
by: Hatice Odabas, et al.
Published: (2023-03-01)

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
by: N. A. Avxentyev, et al.
Published: (2025-05-01)

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
by: Merve Keskinkilic, et al.
Published: (2024-12-01)

CDK 4/6 Inhibitors in Metastatic Hormone Receptor Positive Breast Cancer: An Outcome-Based Study from a Tertiary Care Center in Pakistan
by: Warda Saleem, et al.
Published: (2024-12-01)

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
by: Thanate Dajsakdipon, et al.
Published: (2024-08-01)

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01)

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01)

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania
by: Adina Turcu-Stiolica, et al.
Published: (2024-02-01)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
by: Francesco Schettini, et al.
Published: (2018-12-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer in US routine clinical practice
by: Hope S. Rugo, et al.
Published: (2026-06-01)

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
by: Ahmet Oruç, et al.
Published: (2026-03-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
by: Marcin Kubeczko, et al.
Published: (2024-12-01)

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
by: Marina Elena Cazzaniga, et al.
Published: (2023-10-01)

CDK4/6 Inhibitors for Breast Cancer Therapy—A Review of Clinical Trials, Structural and Computational Approaches
by: Adela Avdičević, et al.
Published: (2026-04-01)

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
by: Elisa Agostinetto, et al.
Published: (2023-11-01)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023-09-01)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
by: Malek Horani, et al.
Published: (2023-10-01)

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
by: Ioana-Miruna Stanciu, et al.
Published: (2023-09-01)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022-03-01)

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer
by: Stephen Chia, et al.
Published: (2025-08-01)

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China
by: Hanfang Jiang, et al.
Published: (2024-05-01)

Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy
by: Federico Sottotetti, et al.
Published: (2025-05-01)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
by: Xing Huang
Published: (2019-11-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)